(Q57415259)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

M H Lee

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

S L Stocker

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

J Anderson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

E J Phillips

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

D Nolan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

K M Williams

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

G G Graham

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

J R Sullivan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

1 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

Internal Medicine Journal

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

411-416

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

Acute adverse reactions attributed to allopurinol in hospitalised patients

8 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

Delayed drug hypersensitivity reactions - new concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

Allopurinol hypersensitivity syndrome: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

A method for estimating the probability of adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

Immune mechanism of drug hypersensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02567.X

10.1111/J.1445-5994.2011.02567.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21790926%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference